Do plasma and urine trypsinogen activation peptides (TAP) really increase in trypsin-taurocholate-induced pancreatitis?

Plasma and urine levels of trypsinogen activation peptides (TAP) reflect th e severity of acute pancreatitis in experimental and clinical acute pancrea titis. In trypsin taurocholate-induced pancreatitis in rats, the extrinsic bovine trypsin used for the induction of pancreatitis might influence on th e TAP levels after induction of pancreatitis. The aim of the present study was to elucidate whether infused trypsin itself affects TAP levels in tryps in-taurocholate-induced pancreatitis. Rats were divided into three groups. In the pancreatitis group, acute pancreatitis was induced by a retrograde i nfusion of bovine trypsin and sodium taurocholate into the pancreatic duct. In the duct infusion group and peritoneal injection group, a mixture of bo vine trypsin and trypsin inhibitor, ONO-3403, was infused into the pancreat ic duct or the peritoneal cavity. Plasma and urine TAP concentration signif icantly increased in trypsin-taurocholate-induced pancreatitis but not in t he duct infusion and peritoneal injection groups for 6 hours after the infu sion of trypsin. Serum rat immunoreactive trypsin (IRT) and amylase signifi cantly increased in the pancreatitis and duct infusion groups but not in th e peritoneal injection group. Serum levels of bovine IRT in the pancreatiti s group was significantly lower than those in duct infusion and peritoneal injection groups. In conclusion, an intraductal infusion of bovine trypsin itself into pancreatic duct does not influence the levels of plasma and uri ne TAP in trypsin-taurocholate-induced pancreatitis.